G1 Therapeutics Price Prediction

GTHXDelisted Stock  USD 7.15  0.00  0.00%   
At this time The value of RSI of G1 Therapeutics' share price is above 80 . This usually indicates that the stock is significantly overbought by investors. The fundamental principle of the Relative Strength Index (RSI) is to quantify the velocity at which market participants are driving the price of a financial instrument upwards or downwards.

Oversold Vs Overbought

86

 
Oversold
 
Overbought
The successful prediction of G1 Therapeutics' future price could yield a significant profit. We analyze noise-free headlines and recent hype associated with G1 Therapeutics, which may create opportunities for some arbitrage if properly timed.
Using G1 Therapeutics hype-based prediction, you can estimate the value of G1 Therapeutics from the perspective of G1 Therapeutics response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in G1 Therapeutics to buy its stock at a price that has no basis in reality. In that case, they are not buying GTHX because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.

G1 Therapeutics after-hype prediction price

    
  USD 7.15  
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as delisted stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.
Intrinsic
Valuation
LowRealHigh
4.845.037.87
Details
Naive
Forecast
LowNextHigh
7.457.647.84
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
7.137.157.16
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as G1 Therapeutics. Your research has to be compared to or analyzed against G1 Therapeutics' peers to derive any actionable benefits. When done correctly, G1 Therapeutics' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in G1 Therapeutics.

G1 Therapeutics After-Hype Price Prediction Density Analysis

As far as predicting the price of G1 Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in G1 Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of G1 Therapeutics, with the unreliable approximations that try to describe financial returns.
   Next price density   
       Expected price to next headline  

G1 Therapeutics Estimiated After-Hype Price Volatility

In the context of predicting G1 Therapeutics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on G1 Therapeutics' historical news coverage. G1 Therapeutics' after-hype downside and upside margins for the prediction period are 6.96 and 7.34, respectively. We have considered G1 Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
7.15
7.15
After-hype Price
7.34
Upside
G1 Therapeutics is very steady at this time. Analysis and calculation of next after-hype price of G1 Therapeutics is based on 3 months time horizon.

G1 Therapeutics Stock Price Prediction Analysis

Have you ever been surprised when a price of a Company such as G1 Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading G1 Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Delisted Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with G1 Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
Expected ReturnPeriod VolatilityHype ElasticityRelated ElasticityNews DensityRelated DensityExpected Hype
  0.03 
0.19
 0.00  
 0.00  
6 Events / Month
4 Events / Month
In about 6 days
Latest traded priceExpected after-news pricePotential return on next major newsAverage after-hype volatility
7.15
7.15
0.00 
211.11  
Notes

G1 Therapeutics Hype Timeline

G1 Therapeutics is currently traded for 7.15. The entity stock is not elastic to its hype. The average elasticity to hype of competition is 0.0. GTHX is forecasted not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is over 100%. The immediate return on the next news is forecasted to be very small, whereas the daily expected return is currently at 0.03%. %. The volatility of related hype on G1 Therapeutics is about 3800.0%, with the expected price after the next announcement by competition of 7.15. About 55.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 0.86. G1 Therapeutics had not issued any dividends in recent years. Given the investment horizon of 90 days the next forecasted press release will be in about 6 days.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.

G1 Therapeutics Related Hype Analysis

Having access to credible news sources related to G1 Therapeutics' direct competition is more important than ever and may enhance your ability to predict G1 Therapeutics' future price movements. Getting to know how G1 Therapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how G1 Therapeutics may potentially react to the hype associated with one of its peers.
Hype
Elasticity
News
Density
Semi
Deviation
Information
Ratio
Potential
Upside
Value
At Risk
Maximum
Drawdown
ALLOAllogene Therapeutics(0.16)9 per month 0.00 (0.05) 9.84 (8.09) 23.67 
HRTXHeron Therapeuti(0.03)7 per month 0.00 (0.17) 4.28 (7.33) 38.90 
ANNXAnnexon 0.00 0 per month 0.00 (0.08) 6.98 (5.26) 23.00 
SGMOSangamo Therapeutics 0.31 9 per month 4.53  0.15  24.14 (7.53) 50.57 
XFORX4 Pharmaceuticals 0.00 0 per month 0.00 (0.07) 6.90 (10.61) 62.35 
HOOKHookipa Pharma 0.00 0 per month 0.00 (0.36) 6.51 (6.67) 22.98 
MREOMereo BioPharma Group 0.00 0 per month 0.00 (0.16) 4.80 (6.31) 17.36 
GRTXGalera Therapeutics(0.02)1 per month 0.00 (0.04) 7.31 (5.84) 18.16 
ABOSAcumen Pharmaceuticals 0.00 0 per month 0.00 (0.06) 7.52 (6.67) 28.07 
ATRAAtara Biotherapeutics 0.00 0 per month 4.90  0.13  19.77 (10.39) 44.50 
FATEFate Therapeutics 0.00 0 per month 0.00 (0.11) 10.63 (7.26) 22.40 
SANASana Biotechnology 0.00 0 per month 0.00 (0.30) 7.20 (8.07) 23.40 
CRBUCaribou Biosciences 0.00 0 per month 4.77 (0.01) 7.42 (6.63) 28.53 
RCUSArcus Biosciences 0.00 0 per month 0.00 (0.1) 4.64 (5.85) 17.22 
DAWNDay One Biopharmaceuticals 0.00 0 per month 0.00 (0.07) 3.84 (3.69) 11.44 
BPMCBlueprint Medicines Corp 0.00 0 per month 2.63 (0.03) 4.90 (3.62) 14.28 
AXSMAxsome Therapeutics 0.00 0 per month 1.91  0.02  4.10 (3.78) 13.67 
PDSBPDS Biotechnology Corp 0.00 0 per month 0.00 (0.11) 7.67 (6.76) 31.83 
AMLXAmylyx Pharmaceuticals 0.00 0 per month 4.14  0.29  10.06 (6.13) 33.56 
CHRSCoherus BioSciences 0.00 0 per month 4.66 (0.02) 8.96 (6.94) 35.06 
LRMRLarimar Therapeutics 0.00 0 per month 0.00 (0.06) 10.87 (9.55) 26.71 
PBYIPuma Biotechnology(0.03)7 per month 4.08  0.06  5.17 (4.95) 33.65 
MGNXMacroGenics(0.17)10 per month 4.56 (0.02) 6.44 (7.01) 19.32 

G1 Therapeutics Additional Predictive Modules

Most predictive techniques to examine GTHX price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for GTHX using various technical indicators. When you analyze GTHX charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.

About G1 Therapeutics Predictive Indicators

The successful prediction of G1 Therapeutics stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as G1 Therapeutics, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of G1 Therapeutics based on analysis of G1 Therapeutics hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to G1 Therapeutics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to G1 Therapeutics's related companies.

Story Coverage note for G1 Therapeutics

The number of cover stories for G1 Therapeutics depends on current market conditions and G1 Therapeutics' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that G1 Therapeutics is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about G1 Therapeutics' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.

G1 Therapeutics Short Properties

G1 Therapeutics' future price predictability will typically decrease when G1 Therapeutics' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of G1 Therapeutics often depends not only on the future outlook of the potential G1 Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. G1 Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding51.7 M
Cash And Short Term Investments82.2 M
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.
You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.

Other Consideration for investing in GTHX Stock

If you are still planning to invest in G1 Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the G1 Therapeutics' history and understand the potential risks before investing.
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world